Anthracyclines and the tailoring of treatment for early breast cancer

New England Journal of Medicine

Volumn 354, Issue 20, 2006, Pages 2177-2179

  Piccart Gebhart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CELL SURFACE RECEPTOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; PHENOBARBITAL; PROGESTERONE RECEPTOR; PROTEIN P53; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; AMENORRHEA; BREAST CANCER; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DOSE RESPONSE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LEUKEMIA; POLYMERASE CHAIN REACTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33646703775     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068065     Document Type: Editorial

References (19)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N. A randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group MA5. J Clin Oncol 2005;23:5166-70.
3. Cardoso F, Atalay G, Piccart MJ. Optimizing anthracycline therapy for node positive breast cancer. Am J Cancer 2002;1:257-68.
4. Piccart-Gebhart MJ. Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapy. J Clin Oncol 2005;23:1611-3.
5. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
6. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
7. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-8.
8. Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 2003;21:458-62.
9. De Laurentiis M, Caputo F, Massarelli E, Forestieri V, Vernaglia A, Carlomagno C. HER2 expression and anthracycline effect: results from the Naple GUN 3 randomized trial. Proc Am Soc Clin Oncol 2001;20:34A. abstract.
10. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topoisomerase IIalpha as predictive markers in a population of nodepositive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001;12:1081-9.
11. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16.
12. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 2005;23:7483-90. [Erratum, J Clin Oncol 2006;24:1015.]
13. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287-97.
14. Arnould L, Fargeot P, Bonneterre J, Fumoleau P, Kerbrat P, Voigt J. Epirubicin dose response effect in node positive breast cancer patients is independent of HER2 overexpression: 10-years retrospective analysis of French Adjuvant Study Group 05 trial. Breast Cancer Res Treat 2003;82:Suppl 1:S130. abstract.
15. Del Mastro L, Bruzzi P, Venturini M, Cavazzini G, Contu A, Gallo L. HER2 expression and efficacy of dose-dense anthracycline containing adjuvant chemotherapy in early breast cancer patients. Proc Am Soc Clin Oncol 2004;23:19. abstract.
16. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39:288-97.
17. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6.
18. Press MF, Bernstein L, Sauter G, et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Breast Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. Breast Cancer Res Treat 2005;94:Suppl 1:S54. abstract.
19. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.